Navigation Links
Indevus Pharmaceuticals Announces First Quarter Fiscal 2009 Financial Results
Date:2/4/2009

cash consideration payments (less any required withholding taxes) payable by Endo in the future upon achievement of certain milestones related to NEBIDO(R) (in development for hypogonadism) and octreotide (in development for acromegaly and carcinoid syndrome), two of the Company's primary product candidates. The acquisition will be effected by means of a tender offer for all the outstanding shares of the Company's common stock, followed by a merger in which the holders of any remaining outstanding shares of the Company's common stock will receive the same consideration as the consideration paid to tendering holders of the Company's common stock in the tender offer. The tender offer commenced on January 7, 2009 and is expected to close before the end of the Company's second fiscal quarter of 2009. The tender offer is conditioned upon the tender of a majority of the outstanding shares of the Company's common stock and is also subject to other customary closing conditions. Due to the potential acquisition by Endo, the Company will not be providing 2009 financial guidance. For more detail regarding the tender offer, see "Additional Important Information" set forth below.

Forward Looking Statements

Except for the descriptions of historical facts contained herein, this press release contains forward-looking statements that involve risks and uncertainties that could cause the Company's actual results and financial condition to differ materially from those anticipated by the forward-looking statements. These risks and uncertainties are set forth in the Company's filings under the Securities Act of 1933 and the Securities Exchange Act of 1934 under "Risk Factors" and elsewhere, and include, but are not limited to: dependence on the success of SANCTURA, SANCTURA XR, NEBIDO, VANTAS and SUPPRELIN LA; effectiveness of our sales force; competition and its effect on pricing, spending, third-party relationships and revenues; dep
'/>"/>

SOURCE Indevus Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. Indevus Pharmaceuticals Announces Definitive Merger Agreement With Endo Pharmaceuticals
2. Endo Pharmaceuticals to Acquire Indevus Pharmaceuticals
3. Indevus Pharmaceuticals Announces Third Quarter Fiscal 2008 Financial Results
4. Indevus Pharmaceuticals Provides Update on NEBIDO(R) NDA Status
5. Indevus Pharmaceuticals Licenses European Rights for VANTAS(R) to Orion Corporation
6. Indevus Pharmaceuticals Announces Retirement Plans For Its CEO and Chairman
7. Indevus To Announce First Quarter Fiscal 2008 Financial Results On Thursday, February 7, 2008
8. Indevus Pharmaceuticals To Present at RBC Capital Markets Conference
9. FDA Accepts New Drug Application for NEBIDO(R) Submitted by Indevus
10. Indevus Pharmaceuticals to Present at Upcoming Investor Conferences
11. Skinvisible Signs Dermatology Agreement With RHEI Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... York, New York (PRWEB) September 22, 2014 ... filed against Boston Scientific Corp. continue to move ... in U.S. District Court, Southern District of West ... documents, a new Docket Control Order was issued ... a number of matters pertaining to the upcoming ...
(Date:9/22/2014)... to 40 percent of patients undergoing breast cancer surgery ... all the cancerous tissue in the initial operation. However, ... tested a tool they developed that will help surgeons ... decreasing the chances for repeat operations. ... September 22, 2014 in the Proceedings of the ...
(Date:9/22/2014)... PA (PRWEB) September 22, 2014 An ... for patients to the problem of side-sleeping. "My lower ... side, so I designed a solution to this problem," ... asleep comfortably than to have your arm 'fall asleep.'" ... on his or her side more comfortably. It avoids ...
(Date:9/22/2014)... 2014 The R&D of cancer vaccines ... The statistically important data received from clinical research studies ... The primary challenge to the development of such vaccines ... mechanism of how a human’s immune system works. The ... different individuals owing to known factors with genetics possibly ...
(Date:9/22/2014)... Barbara Bronson Gray HealthDay Reporter ... something every pregnant woman wonders: What can I do to ... taking iron supplements as prescribed may play a role in ... disorder (ASD). The researchers found that mothers of children ... supplements before and during pregnancy than those whose children seem ...
Breaking Medicine News(10 mins):Health News:Transvaginal Mesh Lawsuits Move Forward, With Issuance of New Order in Federal Boston Scientific Litigation, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuits Move Forward, With Issuance of New Order in Federal Boston Scientific Litigation, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Lawsuits Move Forward, With Issuance of New Order in Federal Boston Scientific Litigation, Bernstein Liebhard LLP Reports 4Health News:The fine line between breast cancer and normal tissues 2Health News:World Cancer Vaccines Market Landscape Examined by Kuick Research in New Study Published at MarketPublishers.com 2Health News:World Cancer Vaccines Market Landscape Examined by Kuick Research in New Study Published at MarketPublishers.com 3Health News:World Cancer Vaccines Market Landscape Examined by Kuick Research in New Study Published at MarketPublishers.com 4Health News:Could Low Iron Intake During Pregnancy Raise Autism Risk? 2Health News:Could Low Iron Intake During Pregnancy Raise Autism Risk? 3
... bleeding is three times more likely to occur in ... regular basis despite the safety profile of non-steroidal anti-inflammatory ... as early as three days after starting an ibuprofen ... one of the most favorable safety profiles of all ...
... fund ?28m for research in United Kingdom as part ... eradication of Malaria worldwide. Bill Gates along with his ... international projects for malaria eradication over the next five ... contributed to research of AIDS and cancer, while malaria, ...
... Abhay Bang and Rani Bang are the two Indian Doctors ... of Heroes of Global Health in solving problems in the ... // innovated basic programs, which has reduced the infant mortality ... founders of the Maharashtra-based Society for Education, Action and Research ...
... marrow injury is an early or predisposing event in ... recent // research which appears online on September 23 ... Myelodysplastic syndrome is a heterogeneous group ... or more hematopoietic lineages, clonal evolution and a tendency ...
... transient episodes of bilateral muscle weakness with areflexia ... to narcolepsy. Cataplexy is diagnosed based on clinical ... recently but their usefulness has been limited because ... , ,Used effectively even these screening tests ...
... at Yale University have discovered the 'DCDC2' gene associated ... of children around the world. // , ,The ... 6 according to the researchers. The researchers found that ... formation of brain circuits and this genetic alteration is ...
Cached Medicine News:Health News:Bill Gates to Fund ?28m for Malaria researc 2Health News:TWO India Doctors Listed in TIME for Contribution to Global Health 2Health News:Chromosome 6 has the Dyslexia Gene 2
(Date:9/22/2014)... CHICAGO, Ill. , Sept. 22, 2014 /PRNewswire/ ... data from several clinical studies evaluating potential new ... presented at the upcoming 2014 European Society of ... Madrid, Spain . Data being ... evaluating the safety and efficacy of veliparib (ABT-888), ...
(Date:9/22/2014)... DIEGO , Sept. 22, 2014 Arena Pharmaceuticals, ... company is scheduled to present a corporate overview and ... on Friday, September 26, 2014, at 11:30 a.m. Eastern ... Hotel in New York City . ... will be available under the investor relations section of ...
(Date:9/22/2014)... , September 22, 2014 ... Line Development Market by Product (Equipment, Media and Reagents), ... Engineering & Regenerative medicine, Toxicity Testing, Research, Drug ... published by MarketsandMarkets, analyzes and studies the major ... Browse 114 market data tables and 64 ...
Breaking Medicine Technology:AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting 2AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting 3AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting 4Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference 2Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference 3Cell Line Development Market Worth $3.96 Billion by 2019 2Cell Line Development Market Worth $3.96 Billion by 2019 3Cell Line Development Market Worth $3.96 Billion by 2019 4
... HOUSTON, Jan. 23, 2012  Spine Pain Management, Inc. (OTC.BB: SPIN.PK), ... pleased to update investors on recent developments.    ... The company will present and meet with investors ... The day,s event is in Las Vegas, Nevada.  The ...
... 23, 2012  VentiRx Pharmaceuticals, Inc., a biopharmaceutical company ... 8 (TLR8) agonists for the treatment of cancer, ... that VTX-2337, the Company,s lead small molecule, is ... VTX-2337 directly activates human myeloid dendritic cells (mDCs), ...
Cached Medicine Technology:Spine Pain Management, Inc. Provides Corporate Updates 2VentiRx Pharmaceuticals Publishes Preclinical Data of Novel TLR8 Agonist, VTX-2337, Supporting Its Potential as an Immunotherapeutic Approach in Cancer 2VentiRx Pharmaceuticals Publishes Preclinical Data of Novel TLR8 Agonist, VTX-2337, Supporting Its Potential as an Immunotherapeutic Approach in Cancer 3
High resolution, multi-frequency, HST version of the UST-987-7.5. Provides even greater image detail, better resolution, and penetration....
A rigid version of the popular flexible laparoscopic transducer. It has been proven that a rigid "lap transducer has great utility in the OR for being an extra lifting tool inside the abdomen....
This is a 3D transducer for endovaginal imaging in OB/GYN....
Super High Density, 120 field of view, angled handle, multi-frequency, convex endovaginal transducer....
Medicine Products: